{
  "meta": {
    "title": "Breast_Cancer",
    "url": "https://brainandscalpel.vercel.app/breast-cancer-6e950f08.html",
    "scrapedAt": "2025-11-29T18:24:55.648Z"
  },
  "questions": [
    {
      "id": 53448,
      "choices": [
        {
          "id": 213273,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Family history of breast cancer</span></span></span></p>"
        },
        {
          "id": 213274,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Past history of fibroadenoma</span></span></span></p>"
        },
        {
          "id": 213275,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Advanced age</span></span></span></p>"
        },
        {
          "id": 213276,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Moderate alcohol consumption</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old postmenopausal woman with a family history of breast cancer is concerned about her risk of developing the disease. Her past medical history is significant for fibroadenoma and alcohol use. Which of the following factors most significantly increases her risk for breast cancer?</span></span></p>",
      "unique_key": "Q6181089",
      "question_audio": null,
      "question_video": null,
      "map_id": 25252,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Advanced age</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Advanced age is a significant risk factor for breast cancer. The likelihood of developing breast cancer increases as a woman ages, particularly after menopause. Most breast cancers are diagnosed in women aged 50 years and older. While family history, fibroadenomas, and alcohol consumption are also risk factors for breast cancer, the risk associated with aging is more significant due to the cumulative exposure to estrogen and the increased likelihood of genetic mutations over time.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Family history of breast cancer: </span></strong><span style=\"font-size:12.0pt\">Although a family history of breast cancer is an important risk factor, especially if the cancer occurred in a first-degree relative or involved high-risk genes like BRCA1 or BRCA2, the overall risk increases with age regardless of family history.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Past history of fibroadenoma</span></strong><span style=\"font-size:12.0pt\">: Fibroadenomas are benign breast tumors and are not considered a significant risk factor for developing breast cancer. They are common in younger women and do not significantly increase the risk of breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Moderate alcohol consumption</span></strong><span style=\"font-size:12.0pt\">: While alcohol consumption is associated with an increased risk of breast cancer, the risk level is generally lower compared to the risk associated with advancing age. The risk increases with the amount of alcohol consumed, but age remains a more significant factor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Advanced age is a significant risk factor for breast cancer, with most cases diagnosed in women aged 50 years and older. The risk increases with age due to factors such as cumulative exposure to estrogen and the increased likelihood of genetic mutations over time.</span></span></span></p>",
      "correct_choice_id": 213275,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53449,
      "choices": [
        {
          "id": 213277,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute mastitis </span></span></p>"
        },
        {
          "id": 213278,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ductal ectasia </span></span></p>"
        },
        {
          "id": 213279,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paget disease of the breast </span></span></p>"
        },
        {
          "id": 213280,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Contact dermatitis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old woman presents with a 6-month history of a persistent, itchy rash on her right nipple. The area is also slightly red and crusted. On examination, you note a small amount of clear discharge from the nipple. Which of the following is the MOST likely diagnosis?</span></span></p>",
      "unique_key": "Q1406169",
      "question_audio": null,
      "question_video": null,
      "map_id": 25253,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Paget disease of the breast</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paget disease of the breast. This condition is characterized by eczema-like changes in the nipple, often accompanied by nipple discharge. The underlying cause is usually an underlying ductal carcinoma in situ (DCIS) or invasive ductal carcinoma (IDC) extending into the nipple epidermis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Acute mastitis:</span></strong><span style=\"font-size:12.0pt\"> Mastitis is a breast infection that typically presents with pain, swelling, redness, and fever. It is less likely to cause chronic eczema-like changes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ductal ectasia:</span></strong><span style=\"font-size:12.0pt\"> Ductal ectasia is a benign condition characterized by dilated ducts and thick, sticky nipple discharge, usually green or black in color. It is not typically associated with eczema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Contact dermatitis:</span></strong><span style=\"font-size:12.0pt\"> Contact dermatitis is an allergic skin reaction that can cause a rash. However, it is unlikely to be limited to the nipple and present with nipple discharge.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paget disease of the breast is an important differential diagnosis for patients presenting with chronic nipple eczema and discharge. A biopsy is necessary to confirm the diagnosis and determine the extent of the underlying malignancy.</span></span></p>",
      "correct_choice_id": 213279,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53450,
      "choices": [
        {
          "id": 213281,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cooper&#39;s ligament</span></span></span></p>"
        },
        {
          "id": 213282,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dermal lymphatics</span></span></span></p>"
        },
        {
          "id": 213283,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chest wall</span></span></span></p>"
        },
        {
          "id": 213284,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Skin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with skin changes over her left breast as shown in the image. This finding is most suggestive of the involvement of which of the following?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-115533.jpg\" style=\"height:295px; width:400px\" /></span></span></p>",
      "unique_key": "Q1828528",
      "question_audio": null,
      "question_video": null,
      "map_id": 25254,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Dermal lymphatics</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peau d&#39;orange (&quot;orange peel skin&quot;) is caused by the blockage of dermal lymphatics by cancer cells.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This obstruction leads to edema and thickening of the skin, causing the characteristic dimpled appearance.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cooper&#39;s ligaments:</span></strong><span style=\"font-size:12.0pt\"> These are fibrous bands that support breast tissue, and their involvement would lead to retraction and dimpling but not the widespread skin changes seen in peau d&#39;orange.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Chest wall:</span></strong><span style=\"font-size:12.0pt\"> Chest wall involvement would present with pain, fixation of the breast, and possibly ulceration, but not the specific peau d&#39;orange pattern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Skin:</span></strong><span style=\"font-size:12.0pt\"> While the skin is involved, the primary cause of peau d&#39;orange is the blockage of lymphatic drainage within the dermis, not a primary skin condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peau d&#39;orange is a highly suggestive sign of inflammatory breast cancer due to tumor invasion of the dermal lymphatics. It requires prompt evaluation and diagnosis.</span></span></span></p>",
      "correct_choice_id": 213282,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53451,
      "choices": [
        {
          "id": 213285,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BI-RADS 1 </span></span></p>"
        },
        {
          "id": 213286,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BI-RADS 2 </span></span></p>"
        },
        {
          "id": 213287,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BI-RADS 3 </span></span></p>"
        },
        {
          "id": 213288,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BI-RADS 4</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman undergoes her annual screening mammogram. The radiologist identifies an abnormality which is shown below. There are no associated masses or architectural distortions. Which BI-RADS category is MOST appropriate for this finding?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-115548.jpg\" style=\"height:210px; width:400px\" /></span></span></p>",
      "unique_key": "Q7231836",
      "question_audio": null,
      "question_video": null,
      "map_id": 25255,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) BI-RADS 4</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most appropriate BI-RADS category for this finding is <strong>(D) BI-RADS 4.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Pleomorphic microcalcifications</span></strong><span style=\"font-size:12.0pt\"> are considered suspicious because they can be associated with malignancy, such as ductal carcinoma in situ (DCIS).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While the absence of a mass or distortion might be reassuring, the presence of these microcalcifications alone is enough to warrant further investigation.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">BI-RADS 4</span></strong><span style=\"font-size:12.0pt\"> indicates a suspicious abnormality that has a 2-95% likelihood of being malignant. This category requires tissue sampling, typically with a biopsy, to make a definitive diagnosis.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. BI-RADS 1:</span></strong><span style=\"font-size:12.0pt\"> Negative, normal mammogram</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. BI-RADS 2:</span></strong><span style=\"font-size:12.0pt\"> Benign finding, no further workup needed</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. BI-RADS 3:</span></strong><span style=\"font-size:12.0pt\"> Probably benign, but short-term follow-up is recommended</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pleomorphic microcalcifications on a mammogram are a suspicious finding and should be investigated further with biopsy to rule out malignancy.</span></span></p>",
      "correct_choice_id": 213288,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53452,
      "choices": [
        {
          "id": 213289,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Enucleation</span></span></p>"
        },
        {
          "id": 213290,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wide local excision with 1 cm margin</span></span></p>"
        },
        {
          "id": 213291,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Local radiotherapy</span></span></p>"
        },
        {
          "id": 213292,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mastectomy</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 29-year-old woman presents to her primary care physician with a palpable lump in her left breast that she discovered three weeks ago during a self-examination. She reports that the lump is painless and mobile. A mammography is performed, which is shown in the image. Given the clinical presentation and mammography findings, what is the appropriate treatment for this patient?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-115604.jpg\" style=\"height:490px; width:400px\" /></span></span></p>",
      "unique_key": "Q2708232",
      "question_audio": null,
      "question_video": null,
      "map_id": 25256,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Enucleation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical description and mammographic findings of a round density with smooth borders and popcorn calcification are suggestive of a fibroadenoma, which is a benign breast tumor commonly found in young women. Fibroadenomas are well-circumscribed, mobile, and often painless lumps. The &quot;popcorn calcifications&quot; are characteristic of fibroadenomas and indicate a benign process. Enucleation, or surgical removal, is a treatment option that can be considered if the lump is symptomatic, shows rapid growth, or the patient desires removal for peace of mind. It is a conservative approach that spares breast tissue and is usually done with local anesthesia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><strong> </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Wide local excision with 1 cm margin:</span></strong><span style=\"font-size:12.0pt\"> Is typically reserved for malignant lesions where clear margins are necessary to ensure complete removal of cancerous cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Local radiotherapy</span></strong><span style=\"font-size:12.0pt\">: Is a treatment modality used in the management of breast cancer, not benign lesions like fibroadenomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Mastectomy:</span></strong><span style=\"font-size:12.0pt\"> Or complete removal of the breast, is a more radical treatment generally reserved for invasive breast cancer or high-risk patients and is not indicated for benign lesions such as fibroadenomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibroadenomas are benign breast tumors characterized by mammography findings of round densities with smooth borders and popcorn calcification. They can be managed conservatively with observation or enucleated if symptomatic or upon patient request.</span></span></p>",
      "correct_choice_id": 213289,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53453,
      "choices": [
        {
          "id": 213293,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive ductal carcinoma </span></span></p>"
        },
        {
          "id": 213294,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibrocystic changes </span></span></p>"
        },
        {
          "id": 213295,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibroadenoma </span></span></p>"
        },
        {
          "id": 213296,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phyllodes tumor</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-years-old woman presents with a rapidly enlarging mass in her right breast that has doubled in size over the past 2 months. The mass is now mildly tender to the touch. Ultrasound-guided core needle biopsy done and shown below. Which of the following is the MOST likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-115621.jpg\" style=\"height:440px; width:400px\" /></span></span></p>",
      "unique_key": "Q5904957",
      "question_audio": null,
      "question_video": null,
      "map_id": 25257,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Phyllodes tumor</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Key features supporting this diagnosis:</span></strong></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rapid growth: Phyllodes tumors are known for their rapid growth rate, often doubling in size within a few months.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mild tenderness: While not always present, mild tenderness can be a feature of phyllodes tumors.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leaf-like projections and hypercellular stromal tissue: These are characteristic histopathologic findings of phyllodes tumors. The &quot;leaf-like&quot; pattern refers to the way the tumor grows in a frond-like or finger-like pattern.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Invasive ductal carcinoma:</span></strong><span style=\"font-size:12.0pt\"> While invasive ductal carcinoma is the most common type of breast cancer, it typically does not grow as rapidly as described in this vignette.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Fibrocystic changes:</span></strong><span style=\"font-size:12.0pt\"> Fibrocystic changes are benign and typically do not present with a rapidly enlarging mass.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fibroadenoma:</span></strong><span style=\"font-size:12.0pt\"> Fibroadenomas are benign tumors that typically grow slowly and are well-circumscribed. They are not associated with the leaf-like pattern seen in the biopsy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Phyllodes tumors are uncommon but should be considered in the differential diagnosis of rapidly growing breast masses, particularly when histopathology shows a leaf-like pattern and hypercellular stromal tissue.</span></span></span></p>",
      "correct_choice_id": 213296,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53454,
      "choices": [
        {
          "id": 213297,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chemotherapy alone </span></span></p>"
        },
        {
          "id": 213298,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endocrine therapy alone </span></span></p>"
        },
        {
          "id": 213299,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-HER2 therapy alone </span></span></p>"
        },
        {
          "id": 213300,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Combined endocrine and chemotherapy</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old woman presents with a newly diagnosed invasive ductal carcinoma of the breast. Immunohistochemistry (IHC) reveals that the tumor is strongly positive for both estrogen (ER) and progesterone (PR) receptors, negative for human epidermal growth factor receptor 2 (HER2), and has a low Ki-67 index (&lt;14%). Which of the following treatment options is MOST appropriate for this patient?</span></span></p>",
      "unique_key": "Q2322111",
      "question_audio": null,
      "question_video": null,
      "map_id": 25258,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Endocrine therapy alone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The tumor profile described (ER+, PR+, HER2-, low Ki-67) corresponds to Luminal A subtype, which typically has a good prognosis and is best treated with endocrine therapy alone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chemotherapy alone:</span></strong><span style=\"font-size:12.0pt\"> While chemotherapy can be beneficial in some breast cancers, Luminal A tumors are generally slow-growing and have a better prognosis. Endocrine therapy alone is usually sufficient to manage the disease and improve outcomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Anti-HER2 therapy alone:</span></strong><span style=\"font-size:12.0pt\"> This patient&#39;s tumor is HER2-negative, meaning it does not overexpress the HER2 protein. Therefore, anti-HER2 therapy would not be effective in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Combined endocrine and chemotherapy:</span></strong><span style=\"font-size:12.0pt\"> While some patients with Luminal A tumors may benefit from the addition of chemotherapy, it is typically reserved for those with higher risk features (e.g., larger tumor size, lymph node involvement). In this patient&#39;s case, the low Ki-67 index suggests a low risk of proliferation, making endocrine therapy alone the most appropriate initial treatment choice.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Luminal A breast cancer is hormone receptor-positive and typically responds well to endocrine therapy.</span></span></span></p>",
      "correct_choice_id": 213298,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53455,
      "choices": [
        {
          "id": 213301,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">DCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab) </span></span></span></p>"
        },
        {
          "id": 213302,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AC-T (Doxorubicin, Cyclophosphamide, Paclitaxel) </span></span></span></p>"
        },
        {
          "id": 213303,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TC-AC (Docetaxel, Cyclophosphamide, Doxorubicin) + Anti-PD1 (Immune Checkpoint Inhibitor) </span></span></span></p>"
        },
        {
          "id": 213304,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Letrozole (aromatase inhibitor)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">58-year-old postmenopausal woman is diagnosed with locally advanced breast cancer (LABC) with involvement of the chest wall and skin. Biopsy reveals a hormone receptor (HR)-positive, HER2-negative tumor. Which of the following is the MOST appropriate neoadjuvant chemotherapy (NACT) regimen for this patient?</span></span></p>",
      "unique_key": "Q9033318",
      "question_audio": null,
      "question_video": null,
      "map_id": 25259,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) AC-T (Doxorubicin, Cyclophosphamide, Paclitaxel)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has LABC, which requires NACT.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The tumor is HR-positive and HER2-negative, which is why AC-T is the preferred regimen, especially in postmenopausal women.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp; A. DCHP:</span></strong><span style=\"font-size:12.0pt\"> This regimen includes Trastuzumab and Pertuzumab, which are anti-HER2 therapies not indicated for HER2-negative tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. TC-AC + Anti-PD1:</span></strong><span style=\"font-size:12.0pt\"> This regimen includes an immune checkpoint inhibitor, which is typically reserved for triple-negative breast cancer (TNBC) and is not indicated in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Letrozole</span></strong><span style=\"font-size:12.0pt\">: This is an endocrine therapy and is not suitable for NACT in LABC. It may be used as adjuvant therapy after surgery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The choice of neoadjuvant chemotherapy in LABC depends on the tumor&#39;s hormone receptor and HER2 status. For HR-positive, HER2-negative LABC in postmenopausal women, AC-T is the preferred regimen.</span></span></p>",
      "correct_choice_id": 213302,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53456,
      "choices": [
        {
          "id": 213305,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stage IIIa</span></span></p>"
        },
        {
          "id": 213306,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stage IV</span></span></p>"
        },
        {
          "id": 213307,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stage IIIc</span></span></p>"
        },
        {
          "id": 213308,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stage II</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old woman presents to oncologist after being diagnosed with left breast invasive ductal carcinoma. On examination, two axillary nodes are palpable on the right side. Given the findings, what is the stage of the cancer?</span></span></p>",
      "unique_key": "Q1171389",
      "question_audio": null,
      "question_video": null,
      "map_id": 25260,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Stage IV</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of palpable cervical lymph nodes on the contralateral side (right side when the cancer is in the left breast) suggests the possibility of distant metastatic spread, which is categorized as stage IV in the TNM (Tumor, Nodes, Metastasis) staging system for breast cancer. The TNM system does not typically classify contralateral lymph node involvement as regional lymphadenopathy; instead, it is considered distant metastasis because lymphatic spread to the contralateral cervical nodes is not a typical pattern for local or regional breast cancer spread.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">The stages are as follows:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage II: The cancer is in the breast and may have spread to up to three axillary lymph nodes but not to distant sites.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage IIIa: The cancer has extended into multiple axillary lymph nodes or the nodes are clumped together, but there is no spread to distant organs.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage IIIc: The cancer is found in 10 or more axillary lymph nodes, nodes near the collarbone, or internal mammary nodes, but not to distant organs.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage IV: The cancer has metastasized beyond the regional lymph nodes to distant organs, which could include contralateral lymph nodes or other body areas.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In breast cancer staging, stage IV indicates distant metastasis. This can include metastatic spread to lymph nodes not typically involved in local or regional breast cancer dissemination, such as contralateral cervical lymph nodes. This stage is consistent with the most advanced form of the disease, where the cancer has spread to other parts of the body beyond the breast and regional lymph nodes.</span></span></p>",
      "correct_choice_id": 213306,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53457,
      "choices": [
        {
          "id": 213309,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sentinel lymph node biopsy (SLNB) </span></span></p>"
        },
        {
          "id": 213310,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Axillary lymph node dissection (ALND)</span></span></p>"
        },
        {
          "id": 213311,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">No axillary surgery </span></span></p>"
        },
        {
          "id": 213312,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Observation with serial ultrasounds</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old woman with a newly diagnosed T2N0 invasive ductal carcinoma of the right breast undergoes neoadjuvant chemotherapy (NACT). After NACT, she is restaged as ycT1cN1. Which of the following is the MOST appropriate surgical approach for managing the axilla in this patient?</span></span></p>",
      "unique_key": "Q5787303",
      "question_audio": null,
      "question_video": null,
      "map_id": 25261,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Sentinel lymph node biopsy (SLNB)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In a patient with LABC (locally advanced breast cancer) who has received NACT and is now clinically node-negative (cN0) or cN1, SLNB is the recommended approach. This is because the NACT may have down staged the axillary nodes, and SLNB can accurately assess the need for further axillary surgery.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. ALND:</span></strong><span style=\"font-size:12.0pt\"> ALND is more extensive and associated with greater morbidity than SLNB. It would only be considered if the SLNB is positive.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. No axillary surgery:</span></strong><span style=\"font-size:12.0pt\"> Even though the patient is clinically node-negative after NACT, there is still a risk of residual disease in the axilla. SLNB is necessary to assess this risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Observation with serial ultrasounds:</span></strong><span style=\"font-size:12.0pt\"> While ultrasound can be helpful in monitoring the axilla, it is not a substitute for definitive staging with SLNB.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The management of the axilla in breast cancer has evolved, and SLNB is now the preferred approach for staging the axilla in many cases. The decision between SLNB and ALND depends on clinical and pathological factors.</span></span></p>",
      "correct_choice_id": 213309,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53458,
      "choices": [
        {
          "id": 213313,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Abemaciclib </span></span></p>"
        },
        {
          "id": 213314,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpelisib </span></span></p>"
        },
        {
          "id": 213315,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Olaparib </span></span></p>"
        },
        {
          "id": 213316,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pembrolizumab</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old woman with HR-positive, HER2-negative breast cancer has a PIK3CA mutation detected on tumor genomic testing. Which of the following medications would be most appropriate to add to her treatment regimen?</span></span></p>",
      "unique_key": "Q2270008",
      "question_audio": null,
      "question_video": null,
      "map_id": 25262,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B. Alpelisib</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alpelisib is a PI3K inhibitor specifically indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with PIK3CA mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Abemaciclib:</span></strong><span style=\"font-size:12.0pt\"> Abemaciclib is a CDK4/6 inhibitor, which is approved for HR-positive, HER2-negative breast cancer. However, it is not specifically targeted for PIK3CA mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Olaparib:</span></strong><span style=\"font-size:12.0pt\"> Olaparib is a PARP inhibitor primarily used in breast cancer patients with BRCA1/2 mutations. It is not indicated for PIK3CA mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pembrolizumab:</span></strong><span style=\"font-size:12.0pt\"> Pembrolizumab is an immune checkpoint inhibitor used in some types of triple-negative breast cancer (TNBC). It does not target PIK3CA mutations and is not indicated for HR-positive breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Targeted therapies like Alpelisib can be effective for specific breast cancer mutations.</span></span></span></p>",
      "correct_choice_id": 213314,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53459,
      "choices": [
        {
          "id": 213317,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endocrine therapy </span></span></p>"
        },
        {
          "id": 213318,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trastuzumab </span></span></p>"
        },
        {
          "id": 213319,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Olaparib </span></span></p>"
        },
        {
          "id": 213320,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pertuzumab</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 38-year-old woman with metastatic triple-negative breast cancer (TNBC) has a germline BRCA1 mutation. Which of the following treatments is MOST likely to be effective in this scenario?</span></span></p>",
      "unique_key": "Q5222550",
      "question_audio": null,
      "question_video": null,
      "map_id": 25263,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Olaparib</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Olaparib is a PARP inhibitor specifically indicated for patients with germline BRCA1 or BRCA2 mutations who have HER2-negative metastatic breast cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Endocrine therapy:</span></strong><span style=\"font-size:12.0pt\"> Triple-negative breast cancer (TNBC) lacks hormone receptors (estrogen and progesterone) and HER2 receptors, making it unresponsive to endocrine therapies that target these pathways.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Trastuzumab:</span></strong><span style=\"font-size:12.0pt\"> This is an anti-HER2 therapy specifically designed for HER2-positive breast cancer. TNBC, by definition, is HER2-negative, making Trastuzumab ineffective.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pertuzumab:</span></strong><span style=\"font-size:12.0pt\"> Similar to Trastuzumab, Pertuzumab is also an anti-HER2 therapy and is not indicated for TNBC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PARP inhibitors are a targeted therapy for BRCA-mutated breast cancers.</span></span></p>",
      "correct_choice_id": 213319,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}